- Home
- » Tags
- » Tolterodine
Top View
- Therapeutic Class Overview Urinary Antispasmodics
- Overactive Bladder
- A Straightforward Route to Enantiopure Pyrrolizidines And
- In Vivo Quantitative Autoradiographic Analysis of Brain Muscarinic Receptor Occupancy by Antimuscarinic Agents for Overactive Bladder Treatment
- (12) United States Patent (10) Patent No.: US 6,890,920 B2 Richards Et Al
- Comparison of Efficacy of Prophylactic Ketamine and Dexmedetomidine on Postoperative Bladder Catheter- Related Discomfort
- Management of Incontinence in Older Adults*
- Are Antimuscarinic Drugs Effective Against Urinary Frequency Mediated by Atropine-Resistant Contractions?
- Antihistamine Prior Authorization Review
- 3703-3712-Flavoxate in the Symptomatic Treatment of Overactive Bladder: a Meta-Analysis
- Patients with Dementia and Receiving Tricyclic Antidepressants Or Anticholinergic Agents
- Howcan Heat Illness Be Affected by Medications?
- The Pharmacology of Svt-40776, a New Muscarinic Antagonist for the Treatment of Urinary Incontinence
- Drug Class Review on Agents for Overactive Bladder
- Interactions with Entry & Integrase Inhibitors
- Neemmc Guidelines for Tablet Crushing and Administration Via Enteral Feeding Tubes
- DESCRIPTION DETROL LA Capsules Contain Tolterodine Tartrate. the Active Moiety, Tolterodine, Is a Muscarinic Receptor Antagonist
- Diphenhydramine (E.G., Benadryl)
- The Role of Combination Medical Therapy in Benign Prostatic Hyperplasia
- Muscarinic Acetylcholine Receptor
- End of Life Care: Talking About Hospice
- Newer Agents for the Management of Overactive Bladder BENJAMIN J
- DIAGNOSIS and TREATMENT of OVERACTIVE BLADDER (Non-Neurogenic) in ADULTS: AUA/SUFU GUIDELINE
- Catheter Related Bladder Discomfort Comparison of Ketamine and Tolterodine;For Reduction of Catheter Related Bladder Discomfort
- Medications and Dysphagia Swallowing Risks
- Overactive Bladder Agents
- Anticholinergic Drugs and Dementia
- Report and Evidence Tables
- (12) United States Patent (10) Patent No.: US 6,482,837 B1 Wood (45) Date of Patent: Nov
- Attachment 2
- List of Drugs to Be Avoided by Patients with Congenital Long QT Syndrome
- An Exploration Into Automated Clinical Drug Classification
- Validated Electroanalytical Determination of Flavoxate Hydrochloride and Tolterodine Tartrate Drugs in Bulk, Dosage Forms and Ur
- Tolterodine and Memory: Dry but Forgetful
- (12) United States Patent (10) Patent No.: US 8.481,518 B2 Wood (45) Date of Patent: Jul
- Guidelines for the Administration of Medicines to Adults Via Enteral Tubes Within NHS Grampian
- CLASS a MEDICATIONS CLASS B MEDICATIONS the Recovering
- A Systematic Review and Network Meta-Analysis
- The Toxicology Investigators Consortium Case Registry—The 2011 Experience
- Characterization of Bladder Selectivity of Antimuscarinic Agents on the Basis of in Vivo Drug-Receptor Binding
- Management of Overactive Bladder in Adults
- TITLE: Oxybutynin, Tolterodine, and Darifenacin: Review of Cognitive Adverse Events
- The Efficacy of Resiniferatoxin in Prevention of Catheter Related Bladder Discomfort in Patients After TURP - a Pilot, Randomized, Open Study
- Chemical Name CAS RN Molecular Formula Specific Sops (-)-2Β
- Tolterodine Tartrate 2Mg Film-Coated Tablets Tolterodine Tartrate
- Guidelines for the Administration of Drugs Through Enteral Feeding Tubes
- Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
- Oxybutynin and Tolterodine for Treatment of Neurogenic Detrusor Overactivity: a Pharmacoeconomic Evaluation in the Brazilian Context
- Impact of Anticholinergics on the Aging Brain: a Review and Practical Application
- Validated Electroanalytical Determination of Flavoxate
- Package Leaflet: Information for the Patient
- Muscarinic Receptor Binding Characteristics of Anticholinergic Agents to Treat Overactive Bladder, in Human Bladder and Parotid Gland
- Rationale for the Use of Anticholinergic Agents in Overactive Bladder with Regard to Central Nervous System and Cardiovascular System Side Effects
- Table of Medications That Increase Fall Risk
- Prevent Drug-Drug Interactions with Cholinesterase Inhibitors
- 257 Comparison for Pharmacological Effects
- 502 Muscarinic Receptor Binding Characteristics Of